Hospital
Rchp-Sierra Vista INC
Rchp-Sierra Vista INC was paid $29.77M by Medicaid between Jan 2018 and Dec 2024, across 274 billing codes. Its largest line is 99284, emergency room visit (serious) — 23% of everything it billed.
33Billing provider infoRCHP-SIERRA VISTA INC
SIERRA VISTA, AZ 85635
SIERRA VISTA, AZ 85635
33aNPI1194766543assigned 06/09/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$29.77M
24GClaims786,899
24DCodes billed274
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Arizona
Rank by total paid#14 of 78
Median peer was paid$12.21M
This provider vs. median2.4×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official LAWRENCE, CHARLOTTE controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 125,306 | $4.48M | |
| 2019 | 123,575 | $4.94M | |
| 2020 | 100,317 | $3.99M | |
| 2021 | 110,619 | $4.17M | |
| 2022 | 123,630 | $4.42M | |
| 2023 | 119,446 | $4.22M | |
| 2024incomplete | 84,006 | $3.55M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 23% | 24,378 | 21,118 | $6.96M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 18% | 22,180 | 20,198 | $5.36M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 13% | 12,196 | 10,618 | $3.94M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 13% | 5,773 | 5,122 | $3.89M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 3.7% | 2,402 | 2,148 | $1.10M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 3.7% | 13,540 | 4,424 | $1.10M |
| 71275 | Computed tomographic angiography, chest, with contrast material | 3.5% | 1,986 | 1,740 | $1.03M |
| 59025 | Fetal non-stress test | 2.7% | 4,354 | 2,461 | $813K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 2.6% | 4,612 | 1,717 | $782K |
| 72125 | Computed tomography, cervical spine; without contrast material | 2.4% | 1,624 | 1,452 | $722K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 1.7% | 7,667 | 2,909 | $520K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 1.5% | 10,225 | 3,458 | $442K |
262 more codes
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 1.4% | 7,218 | $414K |
| 80053 | Comprehensive metabolic panel | 1.2% | 36,681 | $363K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 1,308 | $173K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 2,519 | $168K |
| G0378 | Hospital observation service, per hour | <1% | 6,342 | $149K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 2,179 | $142K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 10,029 | $121K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 13,179 | $116K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 5,204 | $91K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,458 | $79K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 427 | $76K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,479 | $63K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,301 | $52K |
| 80074 | <1% | 389 | $51K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,353 | $48K |
| 84702 | <1% | 2,929 | $48K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 471 | $42K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 1,175 | $41K |
| 71045 | Radiologic examination, chest; single view | <1% | 12,958 | $41K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 40 | $38K |
| 76801 | <1% | 913 | $35K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 8,868 | $31K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 906 | $31K |
| 73564 | <1% | 1,090 | $30K | |
| 72100 | <1% | 658 | $25K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 14,929 | $25K |
| 93971 | <1% | 833 | $24K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 7,717 | $24K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 133 | $22K |
| 73130 | <1% | 1,275 | $22K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 5,687 | $21K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 5,919 | $20K |
| 77080 | <1% | 206 | $20K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 20,871 | $20K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 5,488 | $20K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 90 | $19K |
| 97161 | <1% | 1,796 | $19K | |
| 73030 | <1% | 1,243 | $19K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 108 | $18K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 10,761 | $16K |
| 97162 | <1% | 746 | $13K | |
| 73630 | <1% | 1,594 | $13K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 4,383 | $12K |
| 96376 | <1% | 2,054 | $12K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 43,986 | $11K |
| 92523 | <1% | 44 | $11K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 24 | $11K |
| 70486 | <1% | 44 | $11K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 107 | $10K |
| 73610 | <1% | 1,116 | $10K | |
| 86592 | <1% | 2,411 | $10K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 30 | $10K |
| 97597 | <1% | 187 | $9K | |
| 71250 | <1% | 180 | $9K | |
| 70496 | <1% | 40 | $9K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 7,483 | $9K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 30 | $8K |
| 87340 | <1% | 1,173 | $8K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 9,764 | $8K |
| 93970 | <1% | 32 | $8K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 6,457 | $7K |
| 72131 | <1% | 57 | $7K | |
| 97113 | <1% | 225 | $6K | |
| 84703 | <1% | 10,395 | $6K | |
| 73110 | <1% | 668 | $5K | |
| 87081 | <1% | 3,361 | $5K | |
| 80061 | Lipid panel | <1% | 4,289 | $5K |
| 74018 | <1% | 285 | $4K | |
| 76830 | Ultrasound, transvaginal | <1% | 178 | $4K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 37 | $4K |
| 76775 | <1% | 59 | $4K | |
| 94729 | <1% | 14 | $4K | |
| 86705 | <1% | 554 | $4K | |
| 82248 | <1% | 486 | $3K | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 241 | $3K |
| 87400 | <1% | 7,071 | $3K | |
| 81001 | <1% | 15,924 | $3K | |
| 84484 | <1% | 13,571 | $3K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 47 | $3K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,754 | $3K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 3,210 | $3K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 9,866 | $2K |
| 85610 | <1% | 12,411 | $2K | |
| 86140 | <1% | 2,711 | $2K | |
| 72040 | <1% | 66 | $2K | |
| 94664 | <1% | 2,032 | $2K | |
| 87070 | <1% | 1,130 | $1K | |
| 73562 | <1% | 34 | $1K | |
| 82570 | <1% | 1,249 | $1K | |
| 80076 | <1% | 1,774 | $1K | |
| 86787 | <1% | 903 | $1K | |
| 92522 | <1% | 13 | $1K | |
| 73502 | <1% | 156 | $1K | |
| 83880 | <1% | 3,760 | $1K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 557 | $1K |
| 80069 | <1% | 112 | $1K | |
| 82607 | <1% | 893 | $1K | |
| 82805 | <1% | 1,292 | $1K | |
| 86850 | <1% | 3,125 | $967.24 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 60,176 | $887.34 |
| 84439 | <1% | 4,084 | $849.64 | |
| 82670 | <1% | 54 | $820.69 | |
| 87040 | <1% | 4,686 | $817.57 | |
| 85730 | <1% | 9,625 | $812.11 | |
| 96367 | <1% | 145 | $711.11 | |
| 94060 | <1% | 34 | $675.60 | |
| 83605 | <1% | 11,516 | $665.97 | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 2,174 | $627.07 |
| 83690 | <1% | 11,682 | $572.20 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 9,920 | $567.19 |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 21 | $534.21 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,486 | $527.76 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,110 | $515.65 |
| 97165 | <1% | 161 | $506.39 | |
| 82746 | <1% | 473 | $497.61 | |
| 85027 | <1% | 4,066 | $495.38 | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 2,108 | $432.81 |
| 73080 | <1% | 54 | $410.15 | |
| 84403 | <1% | 94 | $397.17 | |
| 85379 | <1% | 3,147 | $396.13 | |
| 97166 | <1% | 15 | $393.64 | |
| 82950 | <1% | 496 | $385.47 | |
| 81003 | <1% | 9,798 | $348.19 | |
| 76870 | <1% | 15 | $345.36 | |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 188 | $326.78 |
| 84550 | <1% | 589 | $322.69 | |
| 83970 | <1% | 13 | $299.06 | |
| 83540 | <1% | 323 | $298.79 | |
| 84030 | <1% | 12 | $295.24 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 9,954 | $273.68 |
| 86900 | <1% | 3,440 | $265.14 | |
| 83735 | <1% | 11,525 | $232.71 | |
| 93976 | <1% | 20 | $221.93 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,058 | $205.15 |
| 84153 | <1% | 84 | $200.95 | |
| 87077 | <1% | 819 | $178.93 | |
| 82247 | <1% | 154 | $173.48 | |
| 80320 | <1% | 5,263 | $162.26 | |
| 86803 | <1% | 988 | $157.08 | |
| 86762 | <1% | 1,125 | $152.53 | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 16 | $149.35 |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 14 | $148.74 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,429 | $146.07 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 12,671 | $137.07 |
| 73090 | <1% | 28 | $135.96 | |
| 82962 | <1% | 6,977 | $135.38 | |
| 73590 | <1% | 30 | $133.89 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 453 | $132.80 |
| 86703 | <1% | 1,353 | $129.88 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 3,840 | $118.72 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,067 | $111.56 |
| J3490 | Unclassified drugs | <1% | 3,391 | $103.63 |
| 87205 | <1% | 1,487 | $103.09 | |
| 84112 | <1% | 204 | $99.92 | |
| 85014 | <1% | 218 | $84.72 | |
| 82550 | <1% | 1,463 | $77.61 | |
| 87420 | <1% | 1,388 | $76.10 | |
| 84144 | <1% | 152 | $73.85 | |
| 86901 | <1% | 3,435 | $70.48 | |
| A9270 | Non-covered item or service | <1% | 7,238 | $62.00 |
| 87147 | <1% | 202 | $50.86 | |
| 84156 | <1% | 213 | $49.02 | |
| 84100 | <1% | 2,001 | $47.57 | |
| 97116 | <1% | 286 | $43.98 | |
| 90715 | <1% | 779 | $42.74 | |
| 82565 | <1% | 13 | $42.28 | |
| 85652 | <1% | 1,580 | $34.96 | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 547 | $34.17 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 102 | $30.49 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 4,403 | $23.62 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 2,146 | $22.35 |
| 84145 | <1% | 897 | $22.21 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 103 | $22.21 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,573 | $22.13 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 805 | $21.47 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 929 | $20.92 |
| 87210 | <1% | 226 | $19.90 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 3,407 | $19.77 |
| 36416 | <1% | 266 | $19.27 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 6,264 | $13.09 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 3,398 | $11.96 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 642 | $11.04 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 4,271 | $10.59 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 164 | $10.32 |
| 86709 | <1% | 599 | $9.88 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,324 | $8.52 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 316 | $7.37 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 419 | $6.05 |
| 82140 | <1% | 124 | $5.34 | |
| J2704 | Injection, propofol, 10 mg | <1% | 4,826 | $4.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 276 | $2.79 |
| S0028 | Injection, famotidine, 20 mg | <1% | 838 | $2.00 |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 457 | $0.64 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 587 | $0.60 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 620 | $0.34 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 3,588 | $0.26 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 1,583 | $0.22 |
| A7521 | Tracheostomy/laryngectomy tube, cuffed, polyvinylchloride (pvc), silicone or equal, each | 0% | 610 | $0.00 |
| 96368 | 0% | 66 | $0.00 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 0% | 1,461 | $0.00 |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | 0% | 782 | $0.00 |
| 80329 | 0% | 2,936 | $0.00 | |
| J1815 | Injection, insulin, per 5 units | 0% | 412 | $0.00 |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 0% | 146 | $0.00 |
| 85018 | 0% | 273 | $0.00 | |
| 82728 | 0% | 425 | $0.00 | |
| J8597 | Antiemetic drug, oral, not otherwise specified | 0% | 300 | $0.00 |
| 82043 | 0% | 346 | $0.00 | |
| 12001 | 0% | 113 | $0.00 | |
| A6223 | Gauze, impregnated with other than water, normal saline, or hydrogel, sterile, pad size more than 16 sq. in., but less than or equal to 48 sq. in., without adhesive border, each dressing | 0% | 467 | $0.00 |
| 88304 | 0% | 168 | $0.00 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | 0% | 99 | $0.00 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | 0% | 988 | $0.00 |
| 20560 | 0% | 77 | $0.00 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 232 | $0.00 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 1,482 | $0.00 |
| 97016 | 0% | 43 | $0.00 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 293 | $0.00 |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 0% | 185 | $0.00 |
| 88342 | 0% | 40 | $0.00 | |
| 97014 | 0% | 68 | $0.00 | |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | 0% | 47 | $0.00 |
| J7999 | Compounded drug, not otherwise classified | 0% | 79 | $0.00 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 13 | $0.00 |
| 84480 | 0% | 13 | $0.00 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | 0% | 16 | $0.00 |
| J0456 | Injection, azithromycin, 500 mg | 0% | 15 | $0.00 |
| 82553 | 0% | 15 | $0.00 | |
| A9585 | Injection, gadobutrol, 0.1 ml | 0% | 63 | $0.00 |
| 84402 | 0% | 12 | $0.00 | |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 16 | $0.00 |
| J3411 | Injection, thiamine hcl, 100 mg | 0% | 18 | $0.00 |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 18 | $0.00 |
| 82010 | 0% | 157 | $0.00 | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 235 | $0.00 |
| J1644 | Injection, heparin sodium, per 1000 units | 0% | 590 | $0.00 |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 179 | $0.00 |
| A4218 | Sterile saline or water, metered dose dispenser, 10 ml | 0% | 102 | $0.00 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 881 | $0.00 |
| 97533 | 0% | 18 | $0.00 | |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | 0% | 107 | $0.00 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 153 | $0.00 |
| 36600 | 0% | 119 | $0.00 | |
| 84466 | 0% | 233 | $0.00 | |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | 0% | 92 | $0.00 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 259 | $0.00 |
| 84481 | 0% | 525 | $0.00 | |
| J7642 | Glycopyrrolate, inhalation solution, compounded product, administered through dme, concentrated form, per milligram | 0% | 170 | $0.00 |
| 86765 | 0% | 28 | $0.00 | |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 118 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 287 | $0.00 |
| S0164 | Injection, pantoprazole sodium, 40 mg | 0% | 186 | $0.00 |
| 86735 | 0% | 28 | $0.00 | |
| 97168 | 0% | 13 | $0.00 | |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 91 | $0.00 |
| 29125 | 0% | 38 | $0.00 | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | 0% | 37 | $0.00 |
| 99152 | 0% | 45 | $0.00 | |
| 93017 | 0% | 41 | $0.00 | |
| 94726 | 0% | 14 | $0.00 | |
| 51702 | 0% | 16 | $0.00 | |
| J1953 | Injection, levetiracetam, 10 mg | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLAWRENCE, CHARLOTTE (SECRETARY)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.